Theobromine

DB01412

small molecule investigational

Deskripsi

Theobromine (3,7-dimethylxanthine) is the principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than theophylline and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)

Struktur Molekul 2D

Berat 180.164
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1118 Data
Deferasirox The serum concentration of Theobromine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Theobromine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Theobromine can be decreased when it is combined with Teriflunomide.
Regadenoson Theobromine may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of Theobromine can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Theobromine.
Allopurinol The serum concentration of Theobromine can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of Theobromine can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of Theobromine can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of Theobromine can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of Theobromine can be increased when Theobromine is used in combination with Febuxostat.
Fluvoxamine The metabolism of Theobromine can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when Theobromine is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when Theobromine is combined with Indacaterol.
Isoniazid The serum concentration of Theobromine can be increased when it is combined with Isoniazid.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with Theobromine.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with Theobromine.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with Theobromine.
Mexiletine The metabolism of Theobromine can be decreased when combined with Mexiletine.
Olodaterol Theobromine may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Theobromine.
Pentoxifylline The serum concentration of Theobromine can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of Theobromine can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Theobromine can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of Theobromine can be increased when it is combined with Propafenone.
Quinine The serum concentration of Theobromine can be increased when it is combined with Quinine.
Quinidine The serum concentration of Theobromine can be increased when it is combined with Quinidine.
Riociguat Theobromine may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of Theobromine can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of Theobromine can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Theobromine.
Probenecid The serum concentration of Theobromine can be increased when it is combined with Probenecid.
Abiraterone The serum concentration of Theobromine can be increased when it is combined with Abiraterone.
Isoprenaline The serum concentration of Theobromine can be decreased when it is combined with Isoprenaline.
Cyproterone acetate The metabolism of Theobromine can be increased when combined with Cyproterone acetate.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Theobromine.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Theobromine.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Theobromine.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Theobromine.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Theobromine.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Theobromine.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Theobromine.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Theobromine.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Theobromine.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Theobromine.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Theobromine.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Theobromine.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Theobromine.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Theobromine.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Theobromine.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Theobromine.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Theobromine.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theobromine.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Theobromine.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Theobromine.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Theobromine.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Theobromine.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Theobromine.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Theobromine.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Theobromine.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Theobromine.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Theobromine.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Theobromine.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Theobromine.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Theobromine.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Theobromine.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Theobromine.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Theobromine.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Theobromine.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Theobromine.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Theobromine.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Theobromine.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Theobromine.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Theobromine.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Theobromine.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Theobromine.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Theobromine.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Theobromine.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Theobromine.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Theobromine.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Theobromine.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Theobromine.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Theobromine.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Theobromine.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Theobromine.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Theobromine.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Theobromine.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Theobromine.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Theobromine.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Theobromine.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Theobromine.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Theobromine.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Theobromine.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Theobromine.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Theobromine.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Theobromine.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Theobromine.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Theobromine.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Theobromine.

Target Protein

Adenosine receptor A1 ADORA1
5'-nucleotidase NT5E
Adenosine receptor A2a ADORA2A
3',5'-cyclic-AMP phosphodiesterase 4B PDE4B

Referensi & Sumber

Synthesis reference: Misako Mizuno, Hiroshi Ashihara, Kouichi Mizuno, Tatsuhito Fujimura, "CAMELLIA SINENSIS GENE ENCODING A CAFFEINE SYNTHESIS ASSOCIATED N-METHYL TRANSFERASE WITH 7-METHYLXANTHINE N3 METHYL TRANSFERASE, THEOBROMINE N1 METHYL TRANSFERASE, AND PARAXANTHINE N3 METHYL TRANSFERASE ACTIVITIES AND USE THEREOF." U.S. Patent US06930227, issued August 16, 2005.
Artikel (PubMed)
  • PMID: 15548587
    Usmani OS, Belvisi MG, Patel HJ, Crispino N, Birrell MA, Korbonits M, Korbonits D, Barnes PJ: Theobromine inhibits sensory nerve activation and cough. FASEB J. 2005 Feb;19(2):231-3. Epub 2004 Nov 17.
  • PMID: 8280834
    Slattery ML, West DW: Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control. 1993 Nov;4(6):559-63.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul